Alcoholic hepatitis – when the patient’s condition requires urgent medical evaluation

Alcoholic hepatitis (AH) is an acute clinical manifestation of alcoholic liver disease that can appear suddenly – often against a background of many years of drinking – and in its severe form is life-threatening. Unlike steatosis, which runs silently, AH can decompensate within days and require immediate hospitalisation. Understanding its clinical presentation, severity assessment scales and therapeutic options is essential for both patients and physicians referring to addiction treatment.

Pathophysiology – from steatosis to acute hepatitis

Alcoholic hepatitis develops on the basis of chronic alcoholic liver damage, though it can occur even with shorter exposure in predisposed individuals. The key mechanism is the transition from simple lipid accumulation to active inflammatory necrosis of hepatocytes driven by several mutually reinforcing pathways.

Acetaldehyde – the product of ethanol metabolism – forms adducts with hepatocyte proteins and DNA, triggering an immune response. Alcohol increases gut barrier permeability to bacterial lipopolysaccharides (LPS, endotoxin), which reach the liver via the portal vein and activate Toll-like receptors (TLR4) on Kupffer cells. Activated Kupffer cells release TNF-alpha, IL-1beta, IL-6 and other pro-inflammatory cytokines that recruit neutrophils and amplify hepatocyte damage.

Histologically, AH is characterised by steatosis, balloon degeneration of hepatocytes, Mallory-Denk bodies, neutrophil-predominant inflammatory infiltrate and varying degrees of fibrosis – often pericentral and perisinusoidal.

Clinical presentation – how to recognise alcoholic hepatitis

Alcoholic hepatitis typically appears in people with a long history of heavy drinking, often after an episode of particularly intensive consumption or – paradoxically – after abrupt cessation of drinking.

Severity assessment – clinical scales determining treatment

Severity assessment in alcoholic hepatitis is critical for therapeutic decisions – particularly the decision to use corticosteroids, which are indicated only in severe forms and potentially harmful in the presence of infection.

Maddrey Discriminant Function (DF)

DF = 4.6 x (patient’s prothrombin time – control prothrombin time) + bilirubin [mg/dl]. DF above 32 defines severe AH and historically indicates 28-day mortality exceeding 35% without treatment. This is the threshold above which guidelines recommend consideration of corticosteroids.

MELD score

MELD = 3.78 x ln(bilirubin [mg/dl]) + 11.2 x ln(INR) + 9.57 x ln(creatinine [mg/dl]) + 6.43. MELD above 20 in AH corresponds to the severe form and is associated with high short-term mortality. MELD-Na additionally incorporates sodium and is a better predictor of mortality with ascites.

Lille score – assessing response to corticosteroids

The Lille score, calculated after 7 days of corticosteroid treatment, assesses treatment response – bilirubin dynamics taking into account baseline hepatic and renal parameters. A value above 0.45 indicates non-response and is an indication to discontinue corticosteroids – continuing treatment in non-responders increases infection risk without clinical benefit. Lille below 0.45 indicates response and justifies continuing therapy for 28 days.

Differential diagnosis – what to exclude before diagnosing AH

Jaundice with fever and elevated liver enzymes in a person who drinks alcohol requires active exclusion of other causes before establishing the diagnosis of AH and – crucially – before any potential administration of corticosteroids.

Treatment of alcoholic hepatitis – current guidelines

Alcohol abstinence is the cornerstone and most powerful treatment for all forms of AH. For severe AH (DF above 32 or MELD above 20), guidelines from ACG, EASL and AASLD recommend corticosteroids – prednisolone 40 mg orally or methylprednisolone 32 mg intravenously for 28 days, with Lille score assessment after 7 days. Corticosteroids reduce 28-day mortality by approximately 30% in responders, but do not improve 90-day or 6-month survival in meta-analyses.

Nutritional support – enteral or oral, with high protein intake (1.2-1.5 g/kg/day) and calories (35-40 kcal/kg/day) – is an integral part of treatment with documented prognostic impact.

Liver transplantation in selected cases of severe AH not responding to corticosteroids is becoming a therapeutic option in an increasing number of centres. The earlier requirement of 6 months of abstinence before qualification has been challenged – prospective studies show good transplant outcomes in carefully selected patients with a first episode of severe AH.

AH and addiction treatment

Alcoholic hepatitis is not the end of addiction treatment possibilities – it is an urgent indication for it. Every patient who survives an AH episode has documented, directly life-threatening disease caused by alcohol. This is a powerful biological turning point that, with appropriate therapeutic support, can be the beginning of sustained change.

Pharmacotherapy for addiction must be chosen with liver status in mind. Disulfiram is absolutely contraindicated in active hepatitis. Naltrexone requires caution with elevated liver tests. Acamprosate, renally excreted, is safer with impaired liver function. Addiction therapy after an AH episode should be undertaken as soon as possible after general stabilisation – because prognosis with continued drinking is very poor, while prognosis with sustained abstinence is far better than with any pharmacological treatment alone.

Frequently asked questions

References

1. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193-199.
2. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758-2769. doi:10.1056/NEJMra0805786
3. Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619-1628. doi:10.1056/NEJMoa1412278
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Alcohol-related liver disease. J Hepatol. 2018;69(1):154-181.
5. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance. Hepatology. 2020;71(1):306-333.
6. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1790-1800. doi:10.1056/NEJMoa1105703
7. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-194.